Department of International Health, Johns Hopkins Bloomberg School of Public Health (JHBSPH), International Vaccine Access Center (IVAC), Baltimore, MD, USA.
Department of International Health, HealthReveal, New York City, NY, USA.
Expert Rev Vaccines. 2020 Feb;19(2):143-162. doi: 10.1080/14760584.2020.1733419. Epub 2020 Mar 6.
-borne arboviruses contributes substantially to the disease and cost burden. We performed a systematic review of the economic evidence surrounding -borne arboviruses and strategies to prevent and control these diseases to inform disease control policy decisions and research directions. We searched four databases covering an 18-year period (2000-2018) to identify arboviral disease-related cost of illness studies, cost studies of vector control and prevention strategies, cost-effectiveness analyses and cost-benefit analyses. We identified 74 published studies that revealed substantial global total costs in yellow fever virus and dengue virus ranging from 2.1 to 57.3 billion USD. Cost studies of vector control and surveillance programs are limited, but a few studies found that costs of vector control programs ranged from 5.62 to 73.5 million USD. Cost-effectiveness evidence was limited across -borne diseases, but generally found targeted dengue vaccination programs cost-effective. This review revealed insufficient economic evidence for vaccine introduction and implementation of surveillance and vector control programs. Evidence of the economic burden of -borne arboviruses and the economic impact of strategies for arboviral disease prevention and control is critical to inform policy decisions and to secure continued financial support for these preventive and control measures.
虫媒病毒病给疾病和经济负担造成了重大影响。我们对虫媒病毒病及其防控策略的经济证据进行了系统回顾,旨在为疾病防控决策和研究方向提供信息。我们在四个数据库中进行了为期 18 年(2000-2018 年)的搜索,以确定与虫媒病毒病相关的疾病负担研究、病媒控制和预防策略的成本研究、成本效益分析和成本效益分析。我们共发现了 74 篇已发表的研究报告,这些研究报告显示,黄热病病毒和登革热病毒的全球总费用高达 210 亿美元至 5730 亿美元。病媒控制和监测计划的成本研究非常有限,但有一些研究发现,病媒控制计划的成本在 5620 万美元至 7350 万美元之间。针对虫媒病毒病的成本效益证据有限,但一般认为针对登革热的疫苗接种计划具有成本效益。本综述显示,虫媒病毒病的疫苗引入和监测以及病媒控制计划的实施方面的经济证据不足。虫媒病毒病的经济负担和防控策略的经济影响的证据对于决策制定和为这些预防和控制措施提供持续的财政支持至关重要。